SUZHOU, China, July 30, 2024 /PRNewswire/ — On July 29, 2024, Porton Advanced Solutions (“Porton Advanced”) announced that it had reached a strategic cooperation with Guangzhou Geneseed Biotech Co., Ltd (“Geneseed Biotech”). Both sides will combine their respective strengths in the field of gene therapy to jointly provide better drug development services. Leveraging Porton Advanced’s end-to-end cell and gene therapy CDMO service platform and resource advantages, combined with Geneseed Biotech’s comprehensive core patented technologies in circRNA drug concept validation and process development, the two companies will jointly propel technological innovation and clinical translation, thereby accelerating the implementation of innovative circRNA therapies.
Proton Advanced is committed to providing end-to-end CDMO services for cell and gene therapy, and has extensive experience in nucleic acid therapy process development and GMP production, covering various types including mRNA, saRNA, circRNA, and more. Porton Advanced …